X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Update

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) was the target of a significant decline in short interest in February. As of February 28th, there was short interest totalling 9,480,000 shares, a decline of 14.3% from the February 13th total of 11,060,000 shares. Based on an average daily trading volume, of 4,100,000 shares, the days-to-cover ratio is currently 2.3 days. Currently, 5.7% of the company’s shares are sold short.

X4 Pharmaceuticals Trading Up 1.7 %

NASDAQ XFOR opened at $0.30 on Thursday. X4 Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $1.60. The firm has a 50 day moving average of $0.47 and a two-hundred day moving average of $0.54. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. The stock has a market capitalization of $51.10 million, a PE ratio of -3.33 and a beta of 0.39.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $1.50 target price on shares of X4 Pharmaceuticals in a research note on Friday, February 7th.

Insider Activity

In related news, CEO Paula Ragan sold 76,473 shares of X4 Pharmaceuticals stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $34,412.85. Following the completion of the transaction, the chief executive officer now owns 1,087,386 shares in the company, valued at approximately $489,323.70. The trade was a 6.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Adam S. Mostafa sold 74,773 shares of the firm’s stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $33,647.85. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 202,663 shares of company stock valued at $91,198. 1.62% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On X4 Pharmaceuticals

Large investors have recently bought and sold shares of the business. Cantor Fitzgerald L. P. purchased a new stake in X4 Pharmaceuticals during the 4th quarter worth about $30,000. Verition Fund Management LLC purchased a new position in shares of X4 Pharmaceuticals in the 3rd quarter valued at $30,000. Atria Wealth Solutions Inc. acquired a new stake in X4 Pharmaceuticals during the 4th quarter worth $44,000. Wells Fargo & Company MN raised its stake in X4 Pharmaceuticals by 51.7% during the 4th quarter. Wells Fargo & Company MN now owns 78,518 shares of the company’s stock worth $58,000 after acquiring an additional 26,763 shares in the last quarter. Finally, Bank of America Corp DE lifted its position in X4 Pharmaceuticals by 20.3% in the fourth quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock valued at $98,000 after acquiring an additional 22,485 shares during the last quarter. Hedge funds and other institutional investors own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.